Romidepsin

Istodax is FDA-approved for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy, and for peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior treatment. It is used when the disease has progressed or returned after initial therapy.

Istodax contains the active ingredient romidepsin, which is a histone deacetylase (HDAC) inhibitor. It works by blocking HDAC enzymes, which are involved in gene regulation and cell cycle control. By inhibiting these enzymes, romidepsin can cause cell cycle arrest and trigger apoptosis (programmed cell death) in cancerous T-cells, helping to slow or stop the growth of cancer cells.

Istodax carries important safety warnings, including potential for cardiac toxicity (ECG changes, QT prolongation), significant myelosuppression (low blood counts), tumor lysis syndrome, and infections. Common side effects include nausea, fatigue, vomiting, and loss of appetite. Treatment should be administered under the supervision of a qualified oncologist, and regular blood tests and cardiac monitoring are required during treatment. Patients should inform their healthcare provider of all medications and medical conditions before starting therapy.